Approximately Ten Percent of Inpatients Receiving Antibiotic Treatment Have a Hospital-Acquired Bacterial Infection, According to Findings from Decision Resources and Arlington Medical Resources ...
C. difficile infection recurrence rates were numerically lower with vancomycin than with placebo, though the difference was not significant. However, the results could be clinically meaningful, an ...
Vancomycin (as HCl) 500mg/vial, 1g/vial; lyophilized pwd for IV infusion after reconstitution and dilution. Not for prophylaxis of endophthalmitis. Renal insufficiency. Monitor hearing, blood, renal ...
Purpose. The feasibility of using a limitedsampling algorithm for administration of vancomycin for treatment of vascular-access-related bacteremia in outpatient high flux hemodialysis was investigated ...
COPENHAGEN, Denmark & BUFFALO GROVE, IL.--(BUSINESS WIRE)--Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announced today it has ...
Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today ...
The new doses of Vanco Ready include 150mL, 250mL, and 350mL premixed bags containing 750mg, 1.25g, and 1.75g of vancomycin, respectively. Xellia Pharmaceuticals has received approval for 3 additional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback